MISSION AND PURPOSE

It has become increasingly apparent that inappropriate inflammatory and ineffective immune responses are at the center of many chronic disease states. Direct systemic modulation of these critical pathways however can have severe negative consequences as these are central pathways affecting multiple organ systems.

Vicapsys is focused on leveraging natural pathways in a localized manner in order to achieve beneficial therapies without systemic negative consequences. At the core of Vicapsys technology is a pleiotropic cytokine, CXCL12 that can be optimally formulated to achieve therapeutic outcomes in different indications.

Vicapsys is currently focused on curing Type 1 diabetes through long-term survival of transplanted islet cells using a formulation that inhibits development of the foreign body response and immune protection. Vicapsys is also leveraging its core technology to address the consequences of diabetes (diabetic foot ulcers) and the consequences of localized fibrosis (abdominal adhesions).

History

Company History and Highlights

Platform technology exclusively licensed from Massachusetts General Hospital in 2013
Broad portfolio (8 patent families) of issued and pending applications covering multiple indications/applications of the platform
Platform is broadly divided into cellular and non-cellular product lines
Cellular applications initially targeted to treatment of Diabetes Mellitus Type 1 through pancreatic islet cell transplantation
Feasibility and long-term maintenance of transplanted human islet cells established in non human primate models
Other indications include treatment of diabetic foot ulcers and peritoneal adhesions

1999

Discovery of fugetaxis – purposeful migration of cells away from a chemokine: published Nature Medicine, 2000

2007

Long-term Survival of Transplanted Allogeneic Cells Engineered to Express a T Cell Chemorepellent. Transplantation. 2007

2013

Core patents filed, MGH license concluded, Vicapsys formed

2016

Reducing transplant rejection, non-human primate studies initiated with normal animals

2017

Non-human primate studies using diabetic animals

Management

Federico Pier

Managing director of YPH, LLC a Multifamily office investing in Life Sciences, Energy, and Technology. Mr Pier has more than 25 years of experience in reverse mergers, structured finance, convertible debt and straight equity. He has served as a Senior Director at Oppenheimer & Co, and Managing Director at Bear Stearns. He holds a Bachelors’ degree from the University of North Texas and a Master’s of Business Administration from the Graduate School of Management at the University of Dallas.

Chief Executive Officer

Mark Poznansky, MD, PhD

Dr. Poznansky is an Associate Professor of Medicine at Harvard Medical School and Attending Physician in Infectious Diseases Medicine and Director of the Vaccine and Immunotherapy Center at MGH. Dr. Poznansky is the discoverer of the use of AMD3100 for cancer. His laboratory defines molecular mechanisms for novel immune processes and explores the relevance of these mechanisms to novel approaches to vaccines and immunotherapies for cancer and infectious diseases. He is the scientific founder of a number of spinoff biotech companies from MGH including Celtaxsys, ACTx and Vicapsys.

Chief Scientific Advisor and Founder

Jeffery Wright

Mr. Wright is a Certified Public Accountant with 17 years of finance and accounting experience in both the public and private sectors. Mr. Wright joined Vicapsys Life Sciences in June 2019 as the Controller and has served as the Chief Financial Officer since February 2020. Mr. Wright has served in multiple capacities as both the Controller and Chief Financial Officer for both small biotech and technology Companies in various stages of development and has been involved with their exits and mergers. Mr. Wright holds Master of Professional Accountancy and Bachelor of Business Administration degrees from the Georgia State University Robinson College of Business and is a member of the Georgia Society of Certified Public Accountants.

Chief Financial Officer

Board of Directors

Federico Pier, Chairman

Richard Rosenblum

Mr. Richard Rosenblum is Innovative Payment Solutions Inc.’s President, Chief Financial Officer, and Director, and has served in these roles since July 22, 2021. Mr. Rosenblum has served on the Board of H-Cyte since February 1, 2022. Since its founding in 1994, Richard has served as Chief Executive Officer and Principal at Harborview Capital Advisors LLC., providing strategic advisory services in capital formation, merchant banking and management consulting. He is the owner of Harborview Property Management where he invests and manages in commercial real-estate. Mr. Rosenblum was a Director, President, and Executive Chairman of Alliqua Biomedical Inc. which developed hydrogel manufacturing technology. He has served on the Board of Directors of the Chilton Hospital Foundation. Mr. Rosenblum graduated Summa Cum Laude from SUNY Buffalo with a B.A. in Finance & Accounting.

Dorothy Jordan, DNP

Dr. Dorothy Jordan, Board Member - graduated with a BS in Nursing from East Stroudsburg University, a Masters in Child Health from Emory University, a Post-Masters Certificate in Psychiatric Mental Health from Georgia State University, and a Doctor of Nursing Practice from the University of Tennessee Health Science Center. Dr. Jordan served for many years on the Juvenile Diabetes Research Foundation board, the Camp Kudzu board and currently serves on the advisory board of the Emory University Winship Cancer Institute, the Emory University Child and Adolescent Mood Program.

Frances Toneguzzo, Ph.D., CEO

Dr. Toneguzzo has served in multiple strategic roles including as Executive Vice President, Strategic Alliances at Nantkwest Inc, a clinical stage public cell therapy company in the immune-oncology space, managing corporate and academic alliances and intellectual property protection. She also has served as head of IP strategy for Life Biosciences, developing therapies to enhance longevity. Dr. Toneguzzo previously led Partners HealthCare’s efforts related to international and national collaboration and has unique experience in building and executing high value partnerships to commercialize life science innovations During her 12-year tenure, she increased licensing revenues by a consistent 20% year over year and oversaw the launching of 73 startups in areas such as aesthetic dermatology, diagnostics and pharmaceuticals. She comes from the biotech industry, having played various technical and business development roles. She holds a Ph.D. in Biochemistry from McMaster University in Canada.

Colleen Delaney, MD

Dr. Colleen Delaney is the Scientific Founder, Chief Scientific Officer, and Executive Vice President of Research and Development at Deverra Therapeutics, Inc., a cellular therapy company focused on the development of universal donor, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases. Additionally, Dr. Delaney is a stem cell transplant physician and an Affiliate and former Professor of the Fred Hutchinson Cancer Research Center, Clinical Research Division, where she was Physician Investigator (PI) of an NIH/government funded laboratory and where she established and became the Director of the Program in Cord Blood Transplant and Cord Blood Research at the Fred Hutch/Seattle Cancer Care Alliance. Dr. Delaney’s research interests focus on the development of methods to expand the number of umbilical cord blood stem cells and to then direct these cells to further differentiate into mature blood and immune cells for clinical application. She has more than 20 years of experience in the development of cord blood derived allogeneic cell therapies from bench to bedside and is an inventor on numerous patents. Dr. Delaney received her MSc from Oxford University, her MD from Harvard Medical School, and is the recipient of numerous awards, including the prestigious Damon Runyon Foundation Clinical Investigator Award; the Dr. Ali Al-Johani Award in recognition of exemplary clinical medical care and compassion to patients and families; the Seattle Business Journal’s Leaders in Health Care Award for Outstanding Medical Research; and the Seattle American Women in Science’s Award for the Scientific Advancement and Leadership in STEM.

Charles Farrahar

Mr. Charles “Charlie” Farrahar is a Certified Public Accountant with over 30 years of managerial finance, administration, human resource, investor relations, and risk management experience in the public, private and non-profit sectors. Mr. Farrahar served as the Chief Financial Officer of ViCapsys from its inception in 2014 through its merger with SSGI to become a public entity. He has served as CFO for several small biotech startups in various stages of development and has been involved with their exits or mergers. Currently he serves as CFO for a privately-held biotech company headquartered in Rochester, MN that licenses a platform technology from Mayo Clinic. In addition to his prior work with ViCapsys, Mr. Farrahar was the CFO of Credit Depot Corp, Medovex Corp, and Roadie Inc. Mr. Farrahar received his B.B.A. in Accounting from Georgia State University.

LEVERAGING THE BODY’S NATURAL MECHANISMS

Multiple activities of CXCL12 for different applications

Key CXCL12 Discoveries

Repulses Effector T cells and recruits Regulatory T cells to create an immune-privileged environment
Permits and promotes the survival of transplanted β-Islet cells
Promotes Anti-inflammatory and subsequently anti-fibrotic processes preventing post-surgical adhesions
Promotes angiogenesis and recruits endogenous stem cells for the promotion of wound healing

Schematic of the CXCL12 Cellular Actions

Two Product Lines

Vicapsys™

Cell-based therapeutics containing CXCL12

ViBrin™

CXCL12-based therapeutics without cells

CXCL12 Protects Insulin Producing Cells

CXCL12-BASED THERAPIES IN DEVELOPMENT

ViCapsyn™

DIABETES TREATMENT BY β ISLET STEM CELL TRANSPLANTATION
Allogenic Human Stem Cells differentiated into β-cells to produce Insulin

Transplanted in a matrix of an alginate containing CXCL12
Rodent and NHP results indicate cell survival and glucose modulating function up to 6 months posttransplantation

ViBrin™

TO ACCELERATE HEALING OF DIABETIC FOOT ULCERS (DFUs)

CXCL12 complexed into a bioabsorbable polymer and applied directly to the DFU following debridement surgery
Inhibit inflammation, promote stem cell recruitment, angiogenesis to accelerate ulcer healing

ViBrin™

INHIBITING ADHESIONS POST-PERITONEAL SURGERY

CXCL12 formulated in a bioabsorbable, moldable polymer applied to the incision site
Inhibit inflammation and block formation of adhesions

THERAPEUTIC APPLICATIONS

ViCapsyn™ Treatment of Type 1 Diabetes

Diabetes Market Scope

The global treatment market for type 1 diabetes will expand from $6.6b in 2013 to an estimated $13.6b by 2023.
From 2000-2015 diabetes costs in the U.S. nearly doubled, from $12.05 to $23.35 million.
The number of adults living with diabetes has almost quadrupled since 1980.
Diabetes is one of the leading causes of death in the world, and in 2012, was the direct cause of 1.5 million deaths.

Cell Transplantation Program For Type 1 Diabetes

Funded by and developed in partnership with the JDRF
Diabetes Allotransplant Experiments in Non-Human Primates (NHP) are On-Going
Identifying the optimal β-stem cell partner for clinical studies

Immune Response

Alters Innate Immune Response To Omentally-implanted Islets In Animal Models

Concept and Direction

Incorporation of the fugetactic molecule, CXCL12 into an alginate polymer to create an immune-protected environment for transplanted islet cells
CXCL12 alginate formulation helps maintain survival of transplanted islet cells for functionality for extended periods
Human islet stem cells as an autologous or allogeneic cell source produce insulin in response to plasma glucose levels

ViCapsys Data

Data from mouse models and non-human primate studies have demonstrated that islet cells encapsulated in alginate formulations containing CXCL12 are protected from fibrotic overgrowth and foreign body response.

Fibrosis Free

Majority of Microencapsulated SC-Islets Are Fibrosis Free and Maintain Glucose-Responsiveness Up to 6 Months

Eliminates Immune Rejection

VICAPSYN™ Eliminates Immune Rejection of Transplanted Islets

Approximately 100,000 encapsulated islet equivalents placed into separate non-human primates
Implants were surgically evaluated at 90 days
Periodic blood tests were used to evaluate systemic immune responses

Data Summary

Transplantation Of Islet Cells: Latest For Primate Data Summary

Microencapsulation of human stem-cell (SC) derived islets with CXCL12 minimizes foreign body reaction and supports long term (6 months) function without immunosuppression in a primate
Non-diabetic primates transplanted with SC derived islets maintain glycemic control suggesting a glucose regulated function
SC islets maintained expression of all major endocrine hormones and glucose responsiveness over 6 months
No observed hematology or biochemical dysfunction

Latest Data

Preliminary demonstration of efficacy of stem cell derived beta cell transplantation in the context of healthy primates now out to six months post transplantation. Studies with diabetic primates ongoing

ViBrin™ Treatment of Diabetic Foot Ulcers & Adhesions

Diabetic Foot Ulcer (DFU) Market Scope

Between 1.0 – 3.5 million diabetic patients in the United States have a history of foot ulceration

Adhesions Market Scope

Demand for adhesion barriers surgeries poised to grow at a CAGR of 9.2% between 2016 and 2024
Estimated global market of greater than US$ $USD2.7 Billion by 2020
North America market is expected to be US$ 1.6 Billion during 2016 to 2026

Non-Cellular Program Addresses Two Conditions

TREATMENT OF DIABETIC FOOT ULCERS DFUs
are a significant financial burden to health care systems and significantly impact the Quality of Life indices for patients and their families

PREVENTION OF POST-PERITONEAL SURGERY ADHESIONS
An unmet medical need with more than 10 million patients at risk in the US and 25 million patients globally

Accelerate Healing

A Solution to Accelerate Healing of DFUs and Prevent Recurrence

What are Diabetic Foot Ulcers Diabetic foot ulcers?
(DFUs) are a serious complication of diabetes that result in significant morbidity and mortality.

The Common Pathway of Diabetic Foot Ulcer Occurrence and Recurrence

Repetitive external or minor trauma
Trauma leads to a subcutaneous hemorrhage
Hemorrhage results in DFU

Current Status

Current Status of DFU Treatment

The standard practices in DFU management include surgical debridement, dressings to facilitate a moist wound environment and exudate control, wound off-loading, vascular assessment, and infection and glycemic control
DFUs are responsible for more than 80.0% of all diabetes-related lower-leg amputations and occur in around 15.0% of diabetic patients
Even after successful treatment, 40% of patients recur after 1 year and 60% of patients recur after 3 years
Mortality rates associated with development of a DFU are estimated to be 5% in the first 12 months, and 5-year morality rates have been estimated at 42%

Our Concept

The Vicapsys Concept and Direction of DFU Treatment and Care

How we leverage our CKCL12 platform into a therapy:

CXCL12 is complexed into a bioabsorbable polymer and applied directly to the DFU following debridement surgery
Our compound Inhibits inflammation, promotes stem cell recruitment, and angiogenesis to accelerate ulcer healing
Evaluation of single agent and combinations in validated animal models

Accelerated Healing

Accelerated DFU Healing in Hyperglycemic Mice Treated with Bacteria-Producing CXCL12

Accelerated wound healing by treatment with CXCL12-producing L. reuteri. (A) Wounds receiving no treatment (control), treatment with control L. reuteri (LB), and CXCL12-expressing L. reuteri (LB_CXCL12) at the time of wound induction (0 h) and at 24 h. Wound sizes (B) and accumulated wound surface area at 2 d (C). (D) Fractions of wounds healed by different treatments at days 6, 8, and 10 (control, n = 4; LB, n = 3; LB_CXCL12, n = 8; *P < 0.05).

Prevent Adhesions

A Solution To Prevent Post-Peritoneal Surgery Adhesions

What are Adhesions

An adhesion is a band of scar tissue that binds two parts of tissue or organs together. The tissue develops when the body’s repair mechanisms respond to any tissue disturbance, such as surgery, infection, trauma, or radiation. Adhesions occur after up to 97%of abdominal interventions causing chronic pain, infertility, and intestinal obstruction.

CONCEPT AND DIRECTION

Incorporation of CXCL12 into a biodegradable polymer as a solid polymerized substance or as a solution that polymerizes upon contact with tissue
Application of the CCL12-Polymer at the site of surgical intervention
The presence of CXCL12inhibits the inflammatory and immune system attack at the surgical incision, allowing the tissue to repair without the formation of adhesions
Mouse models and non-human primate studies have demonstrated that microbeads containing CXCL12 protect the surrounding tissue from fibrotic overgrowth and adhesions

Blocks Inflammation

VIBRIN™ Blocks Early Inflammatory Response: Prevention Of Adhesions

Adhesion prevention

Post-Operative Adhesion Prevention

The Main in adhesion Prevention Include:

Improvement of surgical techniques
Limitation of the intra-abdominal organ’s trauma
Application of adjuvant agents to reduce the formation of adhesions
Adjuvant agents are typically an Adhesion-Barrier material inserted into the incision site and frequently have little or no effect

Improvement of surgical techniques
Limitation of the intra-abdominal organ’s trauma
Application of adjuvant agents to reduce the formation of adhesions
Adjuvant agents are typically an Adhesion-Barrier material inserted into the incision site and frequently have little or no effect

[/fusion_tagline_box]

Adhesions are a very common and potentially debilitating consequence following surgeries
In 2009 there were 6.1 million digestive system surgeries and 1.1 million urogenital surgeries in the US. (www.stanfordhealthcare.org)
As many as 97% of all abdominal and pelvic surgeries result in the formation of adhesions which may present clinically as chronic and severe pain, infertility in women and in 3-13% of the cases mortality
The cost to the healthcare system and to the quality of life for the patient is significant
Current preventive therapies are physical adhesion barriers and as evidenced by the high incidence rate of adhesions, they are not effective or difficult to use in the operating room
There is no approved pharmacological intervention to prevent adhesions

Current Market

Adhesion Barriers Currently On The Market

Polytetrafluoroethylene (Preclude^®): largely used in gynecological operations WL Gore and Associates.
Polylactide membrane (Surgiwrap^®) MAST Biosurgery AG, – a clear film attached to the site of incision.
4% Icodextrin solution (Adept^®) (Baxter)
Hyalobarrier^® gel and Hyalobarrier gel endo (Anika Therapeutics and NordicPharma, ) .They are composed of highly purified, auto cross-linked polymers of hyaluronic acid (ACP^®).
Seprafilm^® (Sanofi, Paris, France) Seprafilm adhesion barrier is a medical device for adhesion prevention for patients undergoing abdominal or pelvic laparotomy
Interceed (Barrier, Absorbable, Adhesion: Ethicon, Johnson & Johnson) Interceed(TC7) is a fabric composed of oxidized, regenerated cellulose that was designed to reduce the formation of postsurgical adhesions. 1989

BUT THERE ARE NO LEADERS IN EFFICACY

As many as 97% of all abdominal and pelvic surgeries result in the formation of adhesions which may present clinically as chronic and severe pain, infertility in women and in 3-13% of the cases mortality.

NEWS & EVENTS

Publications

Harnessing CXCL12 signaling to protect and preserve functional β-cell mass and for cell replacement in type 1 diabetes.

Abstract: Type 1 diabetes (T1D) is a complex multifactorial disease characterized by autoimmune destruction of insulin producing pancreatic β cells...

Previous 12

Events

Check here for events we will be attending…